research use only

G10 (STING agonist-1) STING agonist

Name: G10 (STING agonist-1)
Brand: Selleck Chemicals
SKU: S8954
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S8954

G10 (STING agonist-1) is a novel human-specific STING agonist that triggers IFN regulatory factor 3 (IRF3)/ type I interferon (IFN)-associated transcription in human fibroblasts. This compound potently reduces growth of Chikungunya virus (CHIKV) with IC90 of 8.01 μM and blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM.

Chemical Structure

Molecular Weight: 430.88

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S895401 DMSO]63 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.92%

99.92

Related Targets	Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor TNF-alpha ROS Parasite PD-1/PD-L1 TLR Prostaglandin Receptor IFN CXCR Nrf2 NOS CCR NLRP3 eIF AhR IL Receptor Complement System IRAK β-lactamase IDO/TDO PGES NADPH-oxidase FKBP LTR
Related Products	C-176 CCCP H-151 diABZI STING agonist-1 (tautomerism) STING inhibitor C-178 C-171 MSA-2 SN-001 ZSA-51 NVS-STG2 diABZI STING agonist-1 trihydrochloride 2',3'-cGAMP Sodium Salt 3',3'-cGAMP SN-011 Cridanimod C-170 STING Antibody [F1N19]

Chemical Information, Storage & Stability

Molecular Weight	430.88	Formula	C₂₁H₁₆ClFN₂O₃S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	702662-50-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1C(=O)N(C2=C(S1)C=CC(=C2)C(=O)NCC3=CC=CO3)CC4=C(C=CC=C4Cl)F

Solubility

In vitro
Batch:

DMSO : 63 mg/mL (146.21 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.050mg/ml (2.44mM)	Taking the 1 mL working solution as an example, add 50 μL of 21 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.050mg/ml (2.44mM)	Taking the 1 mL working solution as an example, add 50 μL of 21 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	STING ^[1] IRF3/IFN ^[1] CHIKV ^[1] (Cell-based assay) 8.01 μM VEEV ^[1] (Cell-based assay) 24.57 μM
In vitro	G10 (STING agonist-1) induces IFN/IRF3- but not NF-κB-dependent transcription in human fibroblasts, and elicits antiviral activity against New and Old World Alphaviruses. It triggers STING-dependent synthesis and secretion of bioactive interferon, induces IRF3-dependent activity, and promotes innate antiviral mRNA expression in primary human cells.^[1]
In vivo	Because G10 (STING agonist-1)-induced innate immune activation is not observed in murine cells, DMXAA (an analog of this compound, with similar physiological effects) is used in the commonly used mice model of CHIKV infection. STING agonism inhibits CHIKV replication in vivo.^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/26646986/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00840008	Completed	Peptic Ulcer Hemorrhage	McGill University Health Centre/Research Institute of the McGill University Health Centre\|Horizon Health Network\|Queen Elizabeth II Health Sciences Centre\|St-Johns Health Sciences Centre\|Centre hospitalier de l''Université de Montréal (CHUM)\|Jewish General Hospital\|Montreal General Hospital\|Royal Victoria Hospital Canada\|Maisonneuve-Rosemont Hospital\|St Mary''s Hospital London\|Centre Hospitalier Pierre Boucher\|Cité de la Santé Hospital\|Centre Hospitalier Anna Laberge\|Hotel Dieu Hospital\|CHAUQ - Hopital Saint Sacrement and Hopital Enfant Jesus\|CISSS de Chaudière-Appalaches\|Hamilton Health Sciences Corporation\|Unity Health Toronto\|Sunnybrook Health Sciences Centre\|Toronto General Hospital\|York Central Hospital Ontario\|Lakeridge Health Corporation\|Guelph General Hospital\|London Health Sciences Centre\|The Ottawa Hospital\|Queen''s University\|Scarborough General Hospital\|Matsqui-Sumas-Abbotsford General Hospital and Mission Memorial Hospital\|Vancouver General Hospital\|Peter Lougheed Centre/The Calgary General Hospital\|Foothills Medical Centre\|Rockyview General Hospital\|Grey Nuns Hospital\|University of Alberta\|Royal Alexandra Hospital\|Misericordia\|Royal University Hospital Foundation\|Regina General Hospital\|University of Manitoba	September 2008	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):